LSA

What is LSA?

LSA, or lysergic acid amide, is a naturally occurring ergoline alkaloid also known as ergine or LA-111. It is structurally related to LSD, but its amide group is much smaller: LSA has a primary carboxamide, whereas LSD carries two ethyl groups on the amide nitrogen. The difference is important. Although the compounds share the lysergic acid skeleton, their receptor activity and reported effects are not the same.

LSA is found in some plants of the Convolvulaceae family, including species of Argyreia, Ipomoea and Rivea. It is often discussed in connection with Hawaiian baby woodrose and morning glory seeds. These seeds do not contain LSA alone. They may carry a mixture of ergot alkaloids, including isoergine, ergometrine and clavine-type compounds, and their composition can vary between species, batches and even individual seeds.

Natural occurrence and chemical identification

The presence of ergot alkaloids in morning glory seeds is linked to their association with alkaloid-producing fungi. The plants themselves are not necessarily the direct source of every compound detected in the seeds; fungal symbionts can contribute to the alkaloid profile. This helps explain why the composition of seeds sold under the same common name may differ substantially.

In a forensic study of five commercially obtained seed varieties, Nowak and colleagues identified several ergot alkaloids using liquid chromatography coupled to high-resolution mass spectrometry. Only three of the five seed types contained detectable ergot alkaloids. When individual seeds were analysed rather than pooled samples, the concentrations of ergine and ergometrine varied considerably. The study also identified isoforms and other alkaloids, underlining why a seed preparation cannot be treated as a chemically uniform source of LSA. The analytical findings are described in “Identification and determination of ergot alkaloids in Morning Glory cultivars”.

Pharmacology

LSA’s pharmacology is less clearly defined than that of LSD. In a 2013 receptor-profiling study, researchers compared LSA and other alkaloids from Argyreia nervosa with LSD. LSA showed measurable affinity at several serotonin receptors, including 5-HT1A and 5-HT2 sites, but its binding affinity was lower than that of LSD in the assays used. The authors also found predicted interactions with adrenergic and dopaminergic targets. These results suggest a broader pharmacological picture than a simple LSD-like 5-HT2A mechanism, although receptor binding alone does not establish the contribution of each target to the human experience.

The distinction between LSA and LSD is reflected in the human literature. LSA is often described as less strongly psychedelic, while nausea, abdominal discomfort and other autonomic effects are prominent in reports. A lower apparent psychedelic intensity does not necessarily mean a more favourable overall effect profile.

Subjective effects

Human observations of LSA come from a mixture of older clinical reports, poison-centre records, case reports and accounts of seed use. A 2025 systematic review identified 17 studies reporting original human data. Across this literature, the reported effects included changes in perception, euphoria and altered thinking, but also nausea, vomiting, abdominal pain, anxiety and cardiovascular symptoms. The studies were heterogeneous: the material consumed was not always chemically standardized, and reported seed quantities do not translate reliably into a measured amount of LSA.

Physical and perceptual effectsCognitive and emotional effects
  • Gastrointestinal discomfort: nausea, vomiting and abdominal pain are among the most frequently described physical complaints.
  • Autonomic changes: increased blood pressure, tachycardia, dizziness and sweating have been reported.
  • Fatigue and bodily heaviness: some accounts describe lethargy or a sedating physical character rather than pronounced stimulation.
  • Perceptual changes: visual distortions and hallucinations are described, although the intensity varies widely between reports.
  • Neurological symptoms: tremor and, in severe intoxications, seizures have been reported.
  • Changes in mood: euphoria and emotional shifts occur in some accounts.
  • Altered thinking: unusual associations, confusion and changes in the flow of thought are described.
  • Anxiety and fear: apprehension, panic and paranoid thinking have been reported.
  • Hallucinatory experiences: some people describe visual or other perceptual disturbances, but the reports do not establish a consistent pattern.
  • Psychotic symptoms: severe agitation and psychosis-like states appear in a small number of clinical reports.

Across the studies that reported clinical outcomes, the review included 219 patients; 27 (12.3%) required medical attention. This pooled proportion is not a population-level estimate, because the included reports were heterogeneous and often involved selected clinical cases. The review also identified serious outcomes, including hospitalization and a case of posterior reversible encephalopathy syndrome (PRES) considered likely to have been associated with LSA exposure. These reports are not evidence that severe complications are typical, but they show that the effects cannot be reduced to a mild or predictable version of an LSD experience. The authors found no reliable dose–response relationship across the available human studies. Their synthesis is available in the 2025 systematic review of LSA’s pharmacological effects and adverse outcomes.

Why seed preparations are difficult to interpret

One recurring problem in the LSA literature is that people often report the number of seeds consumed rather than an analytically measured exposure. Seed alkaloid concentrations vary, and the other compounds in the material may contribute to the experience or to physical discomfort. Even when a study identifies LSA in a sample, that does not establish that LSA alone caused the reported symptoms.

LSA is a distinct lysergamide with documented human psychoactivity, although its pharmacological profile remains incomplete. Its natural occurrence does not make seed preparations standardized, and comparisons with LSD should remain qualified by the substantial differences in chemistry, reported effects and available clinical evidence.

LSA Products

LSA pellets

LSA pellets

Price range: $473.00 through $2,930.00
Select options
LSA blotters

LSA blotters

Price range: $420.00 through $2,100.00
Select options
LSA liquid

LSA liquid

Price range: $410.00 through $2,882.00
Select options

Scientific Data

Identity and Structure

Chemical NameLSA
Catalog Entity TypeCompound
FormulaC16H17N3O
Molar Mass267.332 g·mol−1
CAS478-94-4
CAS Numbers and Substance Forms478-94-4
SynonymsLysergic acid amide; LSA; LAA; ᴅ-Lysergic acid amide; ᴅ-Lysergamide, d-Lysergamide; LA-111; "Lacy"; 6-Methyl-9,10-didehydroergoline-8β-carboxamide
IUPAC Name(6aR,9R)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
InChIInChI=1S/C16H17N3O/c1-19-8-10(16(17)20)5-12-11-3-2-4-13-15(11)9(7-18-13)6-14(12)19/h2-5,7,10,14,18H,6,8H2,1H3,(H2,17,20)/t10-,14-/m1/s1
InChIKeyGENAHGKEFJLNJB-QMTHXVAHSA-N
SMILESO=C(N)[C@@H]1C=C2C3=CC=CC4=C3C(C[C@@]2([H])N(C1)C)=CN4

Chemical Identifiers

PubChem CID442072
ChemSpider ID390611
ChEBI IDCHEBI:4819
UNII073830XH10
ChEMBL IDChEMBL227213
CompTox DTXSIDDTXSID20893673
ECHA ID100.006.841

Physical Properties

Melting Point135 °C (275 °F) Decomposes

Clinical Data

Drug ClassSerotonin receptor agonist; Serotonergic psychedelic; Hallucinogen; Sedative
Routes of AdministrationOral, intramuscular injection, subcutaneous injection
ATC CodeNone
Pregnancy Category (Source Text)X

Pharmacokinetics

MetabolismHepatic
Onset of Action0.3–3 h (morn. glory seeds)
Duration of Action4–10 h (morn. glory seeds)
ExcretionUrine

Legal Status

Legal Status (Wikipedia Source Text)BR: Class F2 (Prohibited psychotropics)
DE: NpSG (Industrial and scientific use only)
UK: Class A
US: Schedule III
Illegal in France

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=373974